Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation

December 14, 2017 updated by: Daniel Godoy Martinez
The hospitalization for hematopoietic stem cell transplantation (HSCT) impairs the physical functioning and functional capacity, but aerobic physical training and, more recently, inspiratory muscle training, have shown benefits to patients' health submitted to this intervention. However, is not known the effect of aerobic physical training combined with inspiratory muscle training in hospitalized patients for HSCT. The purpose of the study will be verify the safety, feasibility and effects of the training association.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Sample Patients consecutively admitted to Bone Marrow Transplantation Unit - University Hospital of Juiz de Fora - EBSERH will be included. Patients will be monitored from admission to hospital discharge and randomized by drawing on opaque paper for the Combined Physical Training Group (aerobic physical training + inspiratory muscle training) or the Aerobic Physical Training Group.

Interview Volunteers will go through an interview and directed physical examination. All volunteers will respond to Baecke's questionnaire to investigate habitual physical activity levels.

Feasibility and safety assessment of the study The viability of the study will be verified by: 1) recruitment (recruitment of at least 60% of eligible patients); 2) adherence (achievement of at least 70% of the total number of minutes of the scheduled interventions); 3) friction (percentage of patients who started but did not complete the intervention).

Safety will be verified by the number of spontaneous or unexpected reactions and adverse events resulting from the proposed interventions.

Quality of life and fatigue questionnaire To evaluate the quality of life, the European Organization for Research and Treatment of Cancer (EORTC-Quality of Life Questionnaire-C30) will be used.

The fatigue will be evaluated by the Functional Assessment of Cancer Therapy - Fatigue (FACT-F) questionnaire, validated for the Portuguese language in Brazilian cancer patients.

Anthropometric evaluation Height and body weight will be measured and the BMI calculated.

Evaluation of hematological variables, clinical symptoms, duration of neutropenia and duration of hospital stay Data on hematological variables, the presence of clinical symptoms (diarrhea, constipation, nausea, vomiting, pain and fatigue), duration of neutropenia, need for infusion of red blood cells and platelets, and length of hospital stay in patients' files will be collected and collected.

Evaluation of peripheral muscle strength In order to estimate the muscular strength of lower limbs (LIIII), the sit and stand test will be used for one minute. For the assessment of upper limb muscle strength, the mean value of three maximal hand grip exercises with the dominant limb will be calculated by means of the Jamar® upper limb dynamometer.

Assessment of respiratory muscle strength The maximal inspiratory and expiratory pressures will be measured by digital manovacuometry (MVD300®).

Evaluation of functional capacity The six-minute step test is a simplified functional capacity assessment procedure, often used in the clinical setting because of its ease of execution in the hospital setting. Also, to evaluate the functionality will be applied the Time Up and Go Test.

Assessment of blood pressure and heart rate The oscillometric method will be applied, using the DIXTAL2023® device, which automatically assessing blood pressure. The heart rate will be evaluated continuously by standard derivation of the electrocardiogram cable of the DIXTAL 2023® multiparameter monitor and by the Polar® cardiac frequency meter (model RS800cx).

Evaluation of cardiac autonomic control Cardiac autonomic control will be evaluated by heart rate variability (HRV) analysis.

Evaluation of the cardiac autonomic control profile during hospitalization for HSCT It will be assessed after recording the heart rate for 10 minutes on days of hospital: admission, end of chemotherapy, onset and end of neutropenia and on hospital discharge.

Aerobic physical training protocol All patients admitted to the Bone Marrow Transplantation Unit will participate in the aerobic physical training protocol, as indicated by the Standard Operating Procedure of the Physiotherapy Sector of the Rehabilitation Unit, University Hospital of Juiz de Fora - EBSERH. The aerobic physical training protocol will be performed five times a week, once a day and planned as follows: 1) heating (5-10 minutes), consisting of coordination training and resistance exercises; 2) moderate intensity aerobic physical training (10-20 minutes) performed on a lower limb cycle ergometer; 3) Cooling (5-10 minutes), consisting of muscle stretching and breathing exercises. During the aerobic training, heart rate and peripheral oxygen saturation will be recorded every 2 minutes, as well as blood pressure and subjective effort scale (BORG modified) every 5 minutes. The training target zone will be calculated from 50% to 70% of the reserve heart rate.

Inspiratory Muscle Training Protocol Patients will be familiar with the correct technique for inspiratory muscle training, using the Power Breathe® device, breathing through mouthpiece and nasal clip. Individuals will be instructed to maintain diaphragmatic breathing, respiratory rate between 15 and 20 irpm, during 20 minutes daily, five times a week. The protocol will be performed in the sitting position with an established load of 40% of maximal inspiratory pressure for the combined physical training group.

Clinical safety criteria for contraindication or discontinuation of training protocol The criteria will be to increase the heart rate above 20% of the training target zone, initial systolic blood pressure less than 90 or greater than 160mmHg, blood pressure greater than 170/100 mmHg during exercise, initial oxygen saturation less than 90% or desaturation (greater than 4% during exercise), body temperature greater than 38 °C, severe musculoskeletal pain, chest tightness, major dyspnea or tiredness (greater than 6 on the Borg Scale), dizziness, nausea, vomiting, epistaxis, or any active bleeding, loss or obstruction of the central or peripheral access catheter, loss or obstruction of the bladder catheter / nasogastric/enteral catheter and/or at the patient's request. Moreover, the hemoglobin (less than 7 mg/dl), hematocrit (less than 20%) and platelets (less than 10000 m3) will be absolute contraindications to perform protocols.

Statistical treatment All volunteers included in the study will be evaluated statistically by intention-to-treat analysis. The data collected will first be submitted to exploratory analysis through boxplots, to verify measures of central tendency and dispersion, and to test data normality. From this preliminary investigation will be defined the statistical tests to be used.

Study Type

Interventional

Enrollment (Anticipated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
    • Minas Gerais
      • Juiz De Fora, Minas Gerais, Brazil, 36038-330

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients consecutively admitted to Bone Marrow Transplantation-HU-UFJF-EBSERH for allogeneic or autologous HSCT
  • Non-smokers
  • Non-alcoholics
  • Sedentary for at least three months prior to hospitalization
  • Absence of orthopedic limitations and / or cognitive alterations that impede the physical training and the understanding of the evaluation instruments

Exclusion Criteria:

  • Patients hospitalized for post-HSCT complications or for other reasons that do not involve HSCT
  • Patients who develop metastases and graft-versus-host disease during hospitalization

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Aerobic Physical Training
Aerobic Training
Other: Aerobic Training
The aerobic physical training will be perform using a cycle ergometer, during 20 minutes daily, five times a week, with moderate intensity (50-70% of reserve heart rate).
Experimental: Combined Physical Training
Inspiratory Muscle Training Aerobic Training
Other: Aerobic Training
The aerobic physical training will be perform using a cycle ergometer, during 20 minutes daily, five times a week, with moderate intensity (50-70% of reserve heart rate).
Other: Inspiratory Muscle Training
The Inspiratory Muscle Training will be perform using using the Power Breathe® device, during 20 minutes daily, five times a week. The protocol will be performed in the sitting position with an established load of 40% of maximal inspiratory pressure.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximal Inspiratory Pressure Test
Time Frame: On the admission and hospital discharge, an average of 20 to 30 days
The maximal inspiratory pressure will be measured by digital manovacuometry (cmH20)
On the admission and hospital discharge, an average of 20 to 30 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of Aerobic and Inspiratory Muscle Training
Time Frame: During the entire hospitalization, daily, during an average of 20 to 30 days
The feasibility of the study will be verified by recruitment (%), adherence (%) and friction (%).
During the entire hospitalization, daily, during an average of 20 to 30 days
Incidence of Aerobic and Inspiratory Muscle Training - Adverse Events (Safety)
Time Frame: During the entire hospitalization, daily, during an average of 20 to 30 days
Safety will be verified by the number of spontaneous or unexpected reactions and adverse events resulting from the proposed interventions.
During the entire hospitalization, daily, during an average of 20 to 30 days
Quality of Life
Time Frame: On the admission and hospital discharge, an average of 20 to 30 days
To evaluate the quality of life, the European Organization for Research and Treatment of Cancer (EORTC-QLQ-C30) will be used. It will be considered the score of the global health, functional health and symptoms domains.
On the admission and hospital discharge, an average of 20 to 30 days
Fatigue
Time Frame: On the admission and hospital discharge, an average of 20 to 30 days
The fatigue will be evaluated by the total score of Functional Assessment of Cancer Therapy - Fatigue (FACT-F) questionnaire.
On the admission and hospital discharge, an average of 20 to 30 days
Hematological Variables
Time Frame: During the entire hospitalization, daily, during an average of 20 to 30 days
Patient records will be consulted and collected daily in order to verify the white cells, red cells and platelets counts.
During the entire hospitalization, daily, during an average of 20 to 30 days
Clinical Symptoms
Time Frame: During the entire hospitalization, daily, during an average of 20 to 30 days
Patient records will be consulted and collected daily in order to verify the presence of diarrhea, pain, nausea, vomiting, fever, hair loss, fatigue, shortness of breath.
During the entire hospitalization, daily, during an average of 20 to 30 days
Duration of Neutropenia
Time Frame: During the entire hospitalization, daily, during an average of 20 to 30 days
Patient records will be consulted and collected daily in order to verify the number of the days in which the patient will be in neutropenia.
During the entire hospitalization, daily, during an average of 20 to 30 days
Duration of Hospitalization
Time Frame: During the entire hospitalization, daily, during an average of 20 to 30 days
Patient records will be consulted and collected daily in order to verify the number of the days in which the patient will be hospitalized.
During the entire hospitalization, daily, during an average of 20 to 30 days
Muscle Strength of Lower Limbs
Time Frame: On the admission and hospital discharge, an average of 20 to 30 days
The muscular strength of lower limbs (LIIII) will be verified by the sit and stand test will be used for one minute (number of repetitions).
On the admission and hospital discharge, an average of 20 to 30 days
Muscle Strength of Upper Limbs
Time Frame: On the admission and hospital discharge, an average of 20 to 30 days
For the assessment of upper limb muscle strength will be used Jamar® upper limb dynamometer (kgf).
On the admission and hospital discharge, an average of 20 to 30 days
Functional Capacity
Time Frame: On the admission and hospital discharge, an average of 20 to 30 days
The six-minute step test will be used and the number of up and down steps will be considered.
On the admission and hospital discharge, an average of 20 to 30 days
Functionality
Time Frame: On the admission and hospital discharge, an average of 20 to 30 days
The Time Up and Go Test will be used and the time to execute the test will be considered in seconds (s).
On the admission and hospital discharge, an average of 20 to 30 days
Blood Pressure
Time Frame: During the entire hospitalization, daily, during an average of 20 to 30 days
The oscillometric method will be applied, using the DIXTAL2023® device to evaluate the systolic, diastolic and mean blood pressure (mmHg).
During the entire hospitalization, daily, during an average of 20 to 30 days
Heart Rate
Time Frame: During the entire hospitalization, daily, during an average of 20 to 30 days
The heart rate (beats per minute) will be evaluated continuously by standard derivation of the electrocardiogram cable of the DIXTAL 2023® multiparameter monitor and by the Polar® cardiac frequency meter (model RS800cx).
During the entire hospitalization, daily, during an average of 20 to 30 days
Cardiac Autonomic Control
Time Frame: Hospital admission day, the end of chemotherapy day, the beginning and end of neutropenia days and the day of hospital discharge, during an average of 20 to 30 days to study completion.
The cardiac autonomic control will be assessed by the frequency (ms2 and nu) and time domains (ms) of heart rate variability analysis.
Hospital admission day, the end of chemotherapy day, the beginning and end of neutropenia days and the day of hospital discharge, during an average of 20 to 30 days to study completion.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Daniel Godoy Martinez

Investigators

  • Principal Investigator: Daniel G Martinez, PhD, Federal University of Juiz de Fora

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 11, 2017

Primary Completion (Anticipated)

December 31, 2019

Study Completion (Anticipated)

December 31, 2019

Study Registration Dates

First Submitted

December 5, 2017

First Submitted That Met QC Criteria

December 8, 2017

First Posted (Actual)

December 14, 2017

Study Record Updates

Last Update Posted (Actual)

December 18, 2017

Last Update Submitted That Met QC Criteria

December 14, 2017

Last Verified

December 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 78682617.9.0000.5133

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lymphoma

Clinical Trials on Aerobic Training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe